Related Experiment Videos
Adjuvant radiation therapy for pathologic T3 prostate cancer
Arthur T. Porter1, A. Williams, Jeffrey D. Forman
1Professor and Chairman, Radiation Oncology Department, Wayne State University School of Medicine, Detroit, Michigan.
The Canadian Journal of Urology
|June 1, 1997
Summary
Adjuvant radiation therapy after prostate cancer surgery can improve local control and survival for men with locally invasive (T3) cancer. This article discusses optimal timing, treatment volume, and methods to minimize side effects.
Area of Science:
- Oncology
- Radiation Oncology
- Urologic Oncology
Background:
- Locally invasive or T3 prostate cancer is defined by intracapsular and extracapsular tumor extension.
- Adjuvant radiation therapy (ART) is a treatment option following initial management for prostate cancer.
Purpose of the Study:
- To review the role of adjuvant radiation therapy in managing locally invasive (T3) prostate cancer.
- To discuss key areas of debate regarding ART, including timing, treatment volume, and morbidity minimization.
Main Methods:
- Literature review and expert discussion of current evidence and clinical practice guidelines.
- Analysis of factors influencing the decision-making process for adjuvant radiation therapy.
Main Results:
- Adjuvant radiation therapy can eradicate microscopic residual disease in the prostatic bed, improving local control.
- ART may offer a survival benefit for select patients with T3 prostate cancer.
Conclusions:
- Adjuvant radiation therapy is a valuable tool for improving outcomes in T3 prostate cancer.
- Further research and consensus are needed on optimal timing, volume, and techniques to minimize treatment-related side effects.